Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
June 2016—In a joint effort to provide customers with an advanced solution for molecular testing, Siemens and Thermo Fisher Scientific announced a strategic relationship that includes the integration of Thermo Fisher Scientific’s real-time PCR system into Siemens’ Versant kPCR Molecular Solution.
June 2016—Rheonix, in collaboration with New York University College of Dentistry, has received funding from a Small Business Innovation Research Phase I/II Fast-track grant from the National Institute of Dental and Craniofacial Research of the National Institutes of Health to develop a rapid diagnostic for Zika virus infection.
June 2016—Oxford Gene Technology launched its CE-IVD labeled Cytocell Aquarius 1p36/1q25 and 19q13/19p13 Deletion Probe Kit, a fluorescence in situ hybridization kit for the reliable investigation of glial tumors.
June 2016—ArcherDX announced three targeted next-generation sequencing assays to capture and identify known and novel gene fusions, point mutations, and relative expression levels in myeloid and lymphoid origin malignancies. The Archer FusionPlex Blood Cancer panels use Archer’s proprietary Anchored Multiplex PCR to detect known and novel fusions from RNA.
June 2016—BioTek launched the Gen5 3.0 data analysis software for its imaging and microplate detection instruments.
June 2016—The Binding Site Group has entered into an exclusive, definitive agreement with Rockland Immunochemicals to grant Rockland global distribution rights for Binding Site’s line of animal-focused radial immunodiffusion test kits. The RID immunoassay kits incorporate monospecific antibodies in an agarose gel to provide accurate quantitation.
June 2016—Mopec has signed an exclusive agreement to feature Milestone’s MacroPath pro-x macro digital imaging system with its MB800 grossing station.
June 2016—Agena Bioscience and Horizon Discovery Group announced a supply and distribution agreement to launch iPlex reference standards for performance verification of oncology assays used on the MassArray System.
June 2016—Becton Dickinson will collaborate with Sight Diagnostics to introduce the SightDX Parasight Malaria Detection Platform in India. BD will market the platform, the company’s first malaria diagnostics offering, in the Indian diagnostics market.
June 2016—Cepheid announced an agreement with Medline for the distribution of the GeneXpert System and menu of Xpert tests, which includes health care associated infections, critical infectious disease, and sexual health.
